Hologic, Inc. (HOLX)
NASDAQ: HOLX · Real-Time Price · USD
75.19
+0.19 (0.25%)
Dec 15, 2025, 4:00 PM EST - Market closed
Hologic Revenue
In the fiscal year ending September 27, 2025, Hologic had annual revenue of $4.10B with 1.74% growth. Hologic had revenue of $1.05B in the quarter ending September 27, 2025, with 6.23% growth.
Revenue (ttm)
$4.10B
Revenue Growth
+1.74%
P/S Ratio
4.15
Revenue / Employee
$579,986
Employees
7,070
Market Cap
16.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 27, 2025 | 4.10B | 70.20M | 1.74% |
| Sep 28, 2024 | 4.03B | -100.00K | - |
| Sep 30, 2023 | 4.03B | -832.40M | -17.12% |
| Sep 24, 2022 | 4.86B | -769.50M | -13.66% |
| Sep 25, 2021 | 5.63B | 1.86B | 49.14% |
| Sep 26, 2020 | 3.78B | 409.10M | 12.15% |
| Sep 28, 2019 | 3.37B | 149.40M | 4.64% |
| Sep 29, 2018 | 3.22B | 159.10M | 5.20% |
| Sep 30, 2017 | 3.06B | 226.10M | 7.98% |
| Sep 24, 2016 | 2.83B | 127.70M | 4.72% |
| Sep 26, 2015 | 2.71B | 174.30M | 6.89% |
| Sep 27, 2014 | 2.53B | 38.42M | 1.54% |
| Sep 28, 2013 | 2.49B | 489.63M | 24.45% |
| Sep 29, 2012 | 2.00B | 213.30M | 11.92% |
| Sep 24, 2011 | 1.79B | 109.80M | 6.54% |
| Sep 25, 2010 | 1.68B | 42.42M | 2.59% |
| Sep 26, 2009 | 1.64B | -37.37M | -2.23% |
| Sep 27, 2008 | 1.67B | 936.13M | 126.78% |
| Sep 29, 2007 | 738.37M | 275.69M | 59.59% |
| Sep 30, 2006 | 462.68M | 175.00M | 60.83% |
| Sep 24, 2005 | 287.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HOLX News
- 13 days ago - New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration - Business Wire
- 20 days ago - New Clinical Evidence on Hologic's AI-Powered Mammography Solutions Will Be Unveiled at RSNA - Business Wire
- 4 weeks ago - Hologic Introduces Digital Pathology Capabilities With Expanded CE Marking - Business Wire
- 6 weeks ago - Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025 - Business Wire
- 7 weeks ago - Hologic Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hologic, Inc. - HOLX - Business Wire
- 7 weeks ago - Blackstone, TPG to Buy Hologic for Up to $18.3 Billion - WSJ
- 7 weeks ago - Blackstone, TPG to acquire medical device maker Hologic in up to $18.3 billion deal - Reuters
- 7 weeks ago - Hologic to be Acquired by Blackstone and TPG for up to $79 per Share - Business Wire